List of Excipients in Branded Drug NYSTATIN ORAL SUSPENSION

Generic Drugs Containing NYSTATIN ORAL SUSPENSION

Company	Ingredient	NDC	Excipient
Xttrium Laboratories Inc	nystatin	0116-4026	ALCOHOL
Xttrium Laboratories Inc	nystatin	0116-4026	ANHYDROUS CITRIC ACID
Xttrium Laboratories Inc	nystatin	0116-4026	BANANA
Xttrium Laboratories Inc	nystatin	0116-4026	CHERRY
Xttrium Laboratories Inc	nystatin	0116-4026	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in NYSTATIN ORAL SUSPENSION?

# Of NDCs	Excipient
4	ALCOHOL
4	ANHYDROUS CITRIC ACID
1	BANANA
3	CARBOXYMETHYLCELLULOSE SODIUM
1	CHERRY

Nystatin Oral Suspension Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Nystatin oral suspension is a mature, multisource prescription product with limited conventional patent protection and substantial room for formulation differentiation. The strongest commercial opportunities are sugar-free and lower-sugar formulations, improved taste and mouthfeel, preservative reduction, dosing accuracy, and packaging designed for pediatric and geriatric use.

The reference product is generally nystatin oral suspension USP, 100,000 units/mL, administered locally in the mouth for oropharyngeal candidiasis. Product competition is driven more by manufacturing reliability, formulary access, tolerability, retail availability, and contract supply than by active-ingredient exclusivity.

What is nystatin oral suspension used for?

Nystatin oral suspension is an antifungal medicine used to treat candidiasis of the mouth and gastrointestinal tract. It acts locally against susceptible Candida species and has limited systemic absorption when administered orally.[1]

Typical dosing depends on age and clinical circumstances. The product is commonly supplied at 100,000 units/mL in multidose bottles. Patients are generally instructed to retain the suspension in the mouth for as long as practical before swallowing, making taste, viscosity, and mouthfeel commercially relevant formulation attributes.[1]

What dosage form is commercially relevant?

The main commercial dosage form is:

Attribute	Typical product characteristic
Active ingredient	Nystatin
Strength	100,000 units/mL
Route	Oral
Dosage form	Oral suspension
Primary indication	Oropharyngeal candidiasis
Market status	Multisource prescription product
Key users	Infants, children, adults, older patients, immunocompromised patients
Key formulation risks	Taste, sedimentation, dose uniformity, preservative tolerance, microbial control

Nystatin is poorly water-soluble. Suspension design therefore requires control of particle size, wetting, dispersion, viscosity, sedimentation, redispersibility, and dose uniformity.

What excipients are used in nystatin oral suspension?

Commercial nystatin oral suspensions use combinations of suspending agents, sweeteners, preservatives, buffers, humectants, flavors, and vehicle components. Exact compositions differ by manufacturer and must be confirmed against the current product label.[1,2]

Common excipient functions include:

Excipient category	Typical function	Commercial relevance
Sucrose or other sweetener	Taste masking and mouthfeel	Important for pediatric adherence; creates sugar-exposure concerns
Glycerin	Humectant, sweetness, viscosity contribution	Improves mouthfeel and suspension texture
Carboxymethylcellulose sodium	Suspending and viscosity agent	Supports dose uniformity and redispersibility
Methylparaben and propylparaben	Antimicrobial preservation	Supports multidose stability; may limit “clean-label” positioning
Sodium citrate or phosphate systems	pH control and buffering	Supports chemical and microbiological stability
Citric acid	pH adjustment and flavor balance	Can improve taste but may affect oral tolerability
Flavoring agents	Taste masking	Directly affects adherence and product differentiation
Purified water	Vehicle	Required for the aqueous suspension

The critical formulation issue is balance. A suspension that is too thin may sediment rapidly and deliver inconsistent doses. A suspension that is too viscous may be difficult to pour, measure, or swallow. Excessive sweetener can improve palatability while increasing dental and metabolic concerns.

What excipient strategy offers the strongest commercial opportunity?

The strongest opportunity is a differentiated oral suspension that maintains nystatin dose uniformity while improving pediatric acceptability and reducing avoidable excipient burdens.

Sugar-free or reduced-sugar formulation

A sugar-free formulation could target patients with diabetes, caregivers concerned about dental exposure, and institutional formularies seeking lower sugar loads. Candidate approaches include sorbitol, xylitol, sucralose, acesulfame potassium, or combinations of high-intensity sweeteners with polyols.

The principal technical risks are:

• Increased gastrointestinal effects from polyols
• Aftertaste from high-intensity sweeteners
• Changes in viscosity and sedimentation
• Potential impact on preservative performance
• Need for new palatability and stability data

A reduced-sugar product may be easier to formulate than a fully sugar-free product. It could preserve some of the texture and taste contribution of sucrose while lowering total sugar exposure.

Improved taste and mouthfeel

Nystatin suspensions can have a chalky, medicinal, or unpleasant taste because the drug is dispersed rather than dissolved. Taste masking can use:

• Flavor systems selected for pediatric acceptance
• Sweetener combinations
• Polymer-based taste-masking approaches
• Controlled particle size
• pH optimization
• Wetting agents compatible with oral use

Flavor selection should account for the intended age group. Fruit flavors may support pediatric use, while neutral or mint-compatible profiles may be more acceptable for adults. The product should avoid excessive flavor intensity because patients may retain the suspension in the mouth before swallowing.

Lower-preservative or preservative-free formulation

Preservatives are commercially relevant because some patients and caregivers prefer products with fewer excipients. A preservative-reduced or preservative-free presentation could use:

• Single-dose packaging
• Unit-dose cups or oral syringes
• Aseptic manufacturing
• Lower microbial burden through container design
• Validated in-use stability
• Alternative antimicrobial systems, where appropriate

A preservative-free multidose bottle is technically difficult because repeated opening creates microbial contamination risk. Unit-dose packaging may solve that problem but raises manufacturing, packaging, and distribution costs.

Improved suspension performance

Suspension performance can be improved through controlled particle size, optimized wetting, polymer selection, and structured vehicles. Key quality attributes include:

• Assay uniformity throughout the bottle
• Redispersibility after storage
• Sedimentation rate
• Pourability
• Syringe withdrawal performance
• Dose delivery after partial use
• Stability under temperature excursions

A formulation that remains uniformly dispersed with brief shaking may have practical advantages over products requiring vigorous shaking or prolonged redispersion.

What formulations are protected by nystatin oral suspension patents?

Nystatin oral suspension has limited apparent opportunity for classic composition-of-matter patent protection because nystatin is an established active ingredient and the 100,000 units/mL suspension is a mature dosage form.

Commercially relevant protection would more likely involve:

• Novel excipient combinations
• Sugar-free suspension systems
• Taste-masking technology
• Preservative-free unit-dose packaging
• Improved physical stability
• Manufacturing processes
• Container-closure systems
• Specialized dosing devices
• New combinations with oral-care or antifungal agents

A formulation patent would need to claim more than the routine substitution of one sweetener or suspending agent for another. The strongest claims would tie the excipient system to measurable performance, such as improved dose uniformity, reduced sedimentation, enhanced redispersibility, improved palatability, or extended in-use stability.

When does nystatin oral suspension lose exclusivity?

Nystatin oral suspension is already a mature genericized product. The relevant commercial question is not the expiry of basic nystatin exclusivity but the presence of active patents, regulatory exclusivities, trademarks, and product-specific formulation rights.

For a conventional nystatin oral suspension:

Exclusivity category	Commercial assessment
Active-ingredient patent	Not generally relevant for this mature product
Basic dosage-form patent	Limited opportunity
New formulation patent	Possible if technically differentiated
Method-of-use patent	Possible but difficult for established oral candidiasis use
Pediatric exclusivity	Product-specific and generally not a principal barrier
Orphan exclusivity	Not a standard feature of the product
Trademark protection	May remain relevant for branded products
Regulatory market exclusivity	Generally not the principal barrier to generic entry

The FDA Orange Book should be checked for the current reference-listed drug and any listed patents or exclusivity codes before filing or licensing decisions are made.[3]

What is the Orange Book status of nystatin oral suspension?

The Orange Book identifies reference-listed drugs, approved abbreviated applications, therapeutic-equivalence evaluations, and certain patent and exclusivity information.[3] Nystatin oral suspension is generally treated as a conventional multisource prescription product rather than a product protected by an active innovator patent estate.

The Orange Book analysis should focus on:

1. The reference-listed drug for nystatin oral suspension, 100,000 units/mL.
2. The applicable NDA and ANDA entries.
3. Therapeutic-equivalence codes.
4. Any listed patents or exclusivity periods.
5. Differences in inactive ingredients across approved products.
6. Whether a proposed product can use the ANDA pathway.

A generic manufacturer may be able to file an ANDA if its product demonstrates pharmaceutical equivalence and bioequivalence or satisfies the applicable FDA requirements for this locally acting oral dosage form. Inactive-ingredient differences may be acceptable if they do not affect safety, efficacy, or performance.[4]

Are there Paragraph IV challenges for nystatin oral suspension?

Paragraph IV litigation is generally less commercially significant for an established nystatin oral suspension than for recently approved branded products. A Paragraph IV certification would matter only if an applicant were addressing an unexpired listed patent associated with the relevant reference product.

Potential dispute areas could include:

• A novel branded suspension
• A newly approved sugar-free formulation
• A patented taste-masking platform
• A proprietary delivery device
• A formulation with extended in-use stability
• A new indication supported by method-of-use claims

For the conventional product, competition is more likely to arise through ANDA approvals, manufacturing transfers, private-label arrangements, and price competition than through patent litigation.

What FDA regulatory pathway applies to nystatin oral suspension?

A conventional generic nystatin oral suspension would typically pursue an ANDA if it can meet the applicable requirements for sameness, quality, strength, route, dosage form, labeling, and bioequivalence.[4]

A differentiated product may require a different pathway if it relies on:

• A materially different formulation
• A new delivery system
• A new indication
• Clinical claims beyond the reference labeling
• A novel preservative-free multidose system
• A formulation that cannot qualify through a standard ANDA

A 505(b)(2) application could be relevant where the product contains the same active ingredient but relies on new clinical, formulation, delivery, or safety information not supported by a conventional ANDA. The pathway depends on the product’s precise differences and the FDA’s requirements for the applicable locally acting suspension.

How strong is the patent estate for nystatin oral suspension?

The patent estate for a standard nystatin oral suspension is generally weak from an exclusivity perspective but can be strengthened through validated formulation innovation.

Patent target	Relative strength	Commercial value
Nystatin active ingredient	Low for new exclusivity	Low
Conventional sucrose suspension	Low	Low
Generic preservative system	Low	Low
Defined sugar-free excipient platform	Moderate	Moderate
Taste-masking system with performance data	Moderate to high	High if clinically relevant
Preservative-free unit-dose presentation	Moderate	Moderate
Dosing device integrated with suspension	Moderate	Moderate
Manufacturing process with yield or stability advantage	Moderate	Moderate
New clinical indication	Potentially high	Depends on market size

Patent strength will depend on claim breadth, unexpected technical results, freedom-to-operate, enablement, and the ability to distinguish routine formulation optimization from inventive development.

What manufacturing and intellectual-property barriers affect entry?

The main entry barriers are operational rather than patent-based.

Manufacturing barriers

Manufacturers must control:

• Nystatin potency and content uniformity
• Powder wetting and dispersion
• Microbial limits
• Preservative effectiveness
• Sedimentation and redispersibility
• Bottle and closure compatibility
• Filling accuracy
• Labeling and dosing-device performance
• Stability after opening

Nystatin can present potency and dispersion challenges because the active ingredient is not freely soluble in the aqueous vehicle. Raw-material quality, particle-size control, and validated mixing order can materially affect final-product consistency.

Intellectual-property barriers

Potential IP risks include:

• Proprietary flavor systems
• Polymer combinations
• Unit-dose packaging
• Dosing devices
• Suspension-processing methods
• Claims directed to reduced sedimentation or improved redispersibility
• Brand trade dress and trademarks

Freedom-to-operate analysis should cover both drug-product patents and packaging-device rights.

Which companies are challenging the nystatin oral suspension market?

The market is likely to include:

• Established generic pharmaceutical manufacturers
• Specialty oral-care and anti-infective companies
• Contract development and manufacturing organizations
• Private-label suppliers
• Hospital and institutional suppliers
• Compounding pharmacies, where legally permitted

Competition is fragmented because the active ingredient is old, the dosage form is familiar, and the product can be manufactured by multiple suppliers. Differentiation depends on reliable supply, national distribution, payer coverage, pricing, and product usability.

A supplier with a differentiated sugar-free, taste-masked, unit-dose product could target pediatric clinics, hospitals, long-term-care facilities, and pharmacy chains rather than compete solely on lowest price.

What are the revenue and commercial opportunities?

Nystatin oral suspension is unlikely to support premium pricing solely through active-ingredient differentiation. Commercial value is more likely in improving adherence, reducing dispensing friction, and securing supply contracts.

Potential revenue opportunities include:

Opportunity	Target customer	Value proposition
Sugar-free suspension	Diabetes clinics, caregivers, retail pharmacies	Lower sugar exposure
Pediatric taste-masked product	Pediatric prescribers and caregivers	Better acceptance and adherence
Unit-dose presentation	Hospitals and long-term-care facilities	Lower contamination and dosing risk
Oral-syringe-compatible bottle	Retail and pediatric channels	Improved dose accuracy
Preservative-reduced product	Consumer and specialty pharmacy channels	Lower excipient burden
Contract-manufactured private label	Pharmacy chains and distributors	Supply continuity and margin control
Stable formulation for global markets	International distributors	Reduced temperature and logistics risk

Revenue exposure should be modeled using prescription volume, average selling price, payer mix, channel discounts, and expected substitution. Public sources generally do not provide a sufficiently reliable standalone revenue figure for the total nystatin oral suspension category.

How does nystatin oral suspension compare with competing antifungal products?

Nystatin competes with oral gels, troches, lozenges, systemic azoles, and compounded preparations. Its principal advantages are local action, long clinical use, and low systemic exposure. Its disadvantages include taste, dosing frequency, need for contact time in the mouth, and suspension-handling requirements.

Product category	Main advantage	Main limitation
Nystatin oral suspension	Local therapy and established use	Taste and frequent dosing
Miconazole oral gel	Adhesive oral delivery	Drug interactions and age-related restrictions
Clotrimazole troche	Solid dosage form	Requires dissolution in the mouth
Fluconazole tablets or suspension	Systemic exposure and convenient dosing	Drug interactions and systemic safety considerations
Compounded antifungal suspension	Customization	Variable availability and quality controls

Nystatin’s best commercial position is in patients for whom local therapy is preferred and in settings where a familiar, low-cost antifungal is needed.

What settlement agreements and litigation affect the product?

No major settlement framework is generally associated with conventional nystatin oral suspension competition. Litigation exposure is more likely to arise from:

• ANDA patent challenges against a newly reformulated product
• Trade-secret disputes involving manufacturing
• Trademark disputes involving product names or packaging
• Contract-manufacturing disagreements
• Product liability claims related to dosing or contamination
• Regulatory actions involving quality or labeling

For a standard generic product, litigation risk is usually lower than supply-chain, quality, and pricing risk.

Key Takeaways

• Nystatin oral suspension is a mature, multisource product with limited conventional patent protection.
• The standard product is typically nystatin 100,000 units/mL in an aqueous suspension.
• Excipients commonly address sweetness, viscosity, suspension stability, preservation, buffering, and flavor.
• Sugar-free, reduced-sugar, taste-masked, preservative-reduced, and unit-dose products offer the clearest commercial opportunities.
• The principal technical risks are sedimentation, dose uniformity, microbial control, taste, and in-use stability.
• A conventional product is more likely to qualify for an ANDA than a materially differentiated formulation.
• Patent value would come from demonstrated formulation performance, packaging, dosing, or manufacturing improvements.
• Generic-entry risk is high for undifferentiated products because the market is mature and multisource.
• Premium pricing requires measurable patient, caregiver, institutional, or supply-chain benefits.
• Orange Book, DailyMed, FDA labeling, and current patent records should control product-specific regulatory and IP conclusions.[1-4]

Frequently Asked Questions

Can a sugar-free nystatin suspension receive patent protection?

Yes. Patent protection could be available for a defined sugar-free excipient system if the claims include non-obvious formulation features and measurable technical advantages. A simple substitution of sucrose with a known sweetener would face a higher obviousness risk.

Is nystatin oral suspension suitable for an oral syringe?

Yes, if the formulation has adequate redispersibility and the container allows accurate withdrawal. Syringe compatibility should be demonstrated across the bottle’s in-use period and after expected settling.

Can nystatin oral suspension be sold over the counter?

The conventional prescription product is not automatically eligible for over-the-counter sale. OTC conversion would require FDA review of labeling, self-selection, safety, and use conditions.

Does a preservative-free nystatin suspension require unit-dose packaging?

Not necessarily, but a preservative-free multidose aqueous suspension requires strong microbial-control measures and validated in-use stability. Unit-dose packaging is a practical route to reduce repeated-container contamination risk.

What is the best first product-development target?

A pediatric-oriented, sugar-free or reduced-sugar suspension with improved taste, strong redispersibility, and an oral-syringe-compatible package offers the clearest combination of technical differentiation and commercial relevance.

References

1. DailyMed. (n.d.). Nystatin oral suspension prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. United States Pharmacopeia. (2024). Nystatin oral suspension and general chapters for oral liquid dosage forms. United States Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

4. U.S. Food and Drug Administration. (2024). Generic drug development and abbreviated new drug application requirements. https://www.fda.gov/drugs/generic-drugs